Newcastle University E-prints Citation for Item: P53, Skp2, and Dkk3 as Mycn Target Genes and Their Potential Therapeutic Significance

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• [Oncogene].

  2019cited by this paper
• Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

  2014cited by this paper
• The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways

  2013cited by this paper
• Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex

  2013cited by this paper
• Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation

  2013cited by this paper
• The clinicopathological significance of REIC expression in colorectal carcinomas.

  2012cited by this paper
• Overexpression of Dickkopf-3 induces apoptosis through mitochondrial pathway in human colon cancer.

  2012cited by this paper
• Links between mutant p53 and genomic instability

  2012cited by this paper
• Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program

  2012cited by this paper
• The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)

  2012influential reference
• The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.

  2012cited by this paper
• Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3.

  2012cited by this paper
• REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer.

  2012cited by this paper
• The microcosmos of cancer

  2012cited by this paper
• Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

  2012cited by this paper
• Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo.

  2012cited by this paper
• A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation.

  2012cited by this paper
• MiR-122 in hepatic function and liver diseases

  2012cited by this paper
• Linkage between Twist1 and Bmi1: Molecular mechanism of cancer metastasis/stemness and clinical implications

  2012cited by this paper
• Characterization of Gene Amplification–Driven SKP2 Overexpression in Myxofibrosarcoma: Potential Implications in Tumor Progression and Therapeutics

  2012cited by this paper
• Stat3 induces oncogenic Skp2 expression in human cervical carcinoma cells.

  2012cited by this paper
• Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.

  2012cited by this paper
• Cyclotherapy: opening a therapeutic window in cancer treatment

  2012cited by this paper
• Proteasome inhibitors: an expanding army attacking a unique target.

  2012cited by this paper
• The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

  2012cited by this paper
• MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.

  2011cited by this paper
• Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.

  2011cited by this paper
• Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma

  2011cited by this paper
• Nuclear translocation of Skp2 facilitates its destruction in response to TGFβ signaling

  2011cited by this paper
• Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

  2011cited by this paper
• Wnt antagonist DICKKOPF‐3 (Dkk‐3) induces apoptosis in human renal cell carcinoma

  2011cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro.

  2011cited by this paper
• Clinical relevance of SKP2 alterations in metastatic melanoma

  2011cited by this paper
• Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

  2011cited by this paper
• Neuroblastoma therapy: what is in the pipeline?

  2011cited by this paper
• The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

  2011cited by this paper
• Transcriptional Regulation of S Phase Kinase-associated Protein 2 by NR4A Orphan Nuclear Receptor NOR1 in Vascular Smooth Muscle Cells*

  2011cited by this paper
• Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

  2011cited by this paper
• Skp2 is a Promising Therapeutic Target in Breast Cancer

  2011cited by this paper
• MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63

  2011influential reference
• Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression

  2011cited by this paper
• Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma.

  2011cited by this paper
• Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes

  2011cited by this paper
• MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells

  2011cited by this paper
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  2011cited by this paper
• Overexpression of SKP2 Promotes the Radiation Resistance of Esophageal Squamous Cell Carcinoma

  2011cited by this paper
• BMI1 as a novel target for drug discovery in cancer

  2011cited by this paper
• Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

  2011cited by this paper
• P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis

  2010cited by this paper
• STAT1 Represses Skp2 Gene Transcription to Promote p27Kip1 Stabilization in Ras-Transformed Cells

  2010cited by this paper
• Skp2B attenuates p53 function by inhibiting prohibitin

  2010cited by this paper
• Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence

  2010cited by this paper
• p53-based cancer therapy.

  2010cited by this paper
• Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

  2010cited by this paper
• Mutant p53 gain-of-function in cancer.

  2010cited by this paper
• Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication

  2010cited by this paper
• Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma.

  2010cited by this paper
• High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

  2010influential reference
• The p53 response element and transcriptional repression

  2010cited by this paper
• Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells

  2010cited by this paper
• Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis

  2010cited by this paper
• Wnt signaling and its downstream target N-myc regulate basal progenitors in the developing neocortex

  2010cited by this paper
• Analysis of Dickkopf3 interactions with Wnt signaling receptors

  2010cited by this paper
• Translating p53 into the clinic

  2010cited by this paper
• miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma

  2010cited by this paper
• Regulation of Skp2 Expression and Activity and Its Role in Cancer Progression

  2010influential reference
• Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

  2010cited by this paper
• Neuroblastoma: biology, prognosis, and treatment.

  2010cited by this paper
• Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice

  2010cited by this paper
• Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.

  2010cited by this paper
• MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3.

  2010cited by this paper
• Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?

  2009cited by this paper
• The effect on cell growth by Wnt1 RNAi in human neuroblastoma SH-SY5Y cell line

  2009cited by this paper
• Azacitidine for the treatment of myelodysplastic syndrome

  2009cited by this paper
• Suppression of Anoikis by SKP2 Amplification and Overexpression Promotes Metastasis of Esophageal Squamous Cell Carcinoma

  2009cited by this paper
• The expanding universe of p53 targets

  2009cited by this paper
• Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14ARF-MDM2-p53 axis

  2009cited by this paper
• Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

  2009influential reference
• The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway

  2009cited by this paper
• p53 represses c-Myc through induction of the tumor suppressor miR-145

  2009cited by this paper
• Awakening guardian angels: drugging the p53 pathway

  2009cited by this paper
• Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer

  2009cited by this paper
• Reduced levels of miR‐34a in neuroblastoma are not caused by mutations in the TP53 binding site

  2009cited by this paper
• High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.

  2009cited by this paper
• Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

  2009cited by this paper
• New therapeutic targets for the treatment of high‐risk neuroblastoma

  2009cited by this paper
• Cellular quiescence caused by the Mdm2 inhibitor Nutlin-3A

  2009cited by this paper
• Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma.

  2009cited by this paper
• Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.

  2009cited by this paper
• SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells.

  2009cited by this paper
• p53 — a Jack of all trades but master of none

  2009cited by this paper
• Embryonal neural tumours and cell death

  2009cited by this paper
• MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma

  2009cited by this paper
• The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.

  2009cited by this paper
• An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

  2009cited by this paper
• Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.

  2008cited by this paper
• Two distinctly altered cellular responses to DNA double-strand breaks in human neuroblastoma.

  2008cited by this paper
• HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function

  2008cited by this paper
• Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

  2008cited by this paper

• Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target

  2025cites this paper
• Study on the role of MYCN in retinoblastoma by inhibiting p53 and activating wnt/βcatenin/Fra‐1 signaling pathway by reducing DKK3

  2024cites this paper
• Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment

  2022cites this paper
• An Integrative Pan-Cancer Analysis Revealing MLN4924 (Pevonedistat) as a Potential Therapeutic Agent Targeting Skp2 in YAP-Driven Cancers

  2022influential citation
• Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer

  2021cites this paper
• Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

  2020cites this paper
• RNAi Nanotherapeutics for Treatment of Glioblastoma Multiforme.

  2020cites this paper
• The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner

  2020cites this paper
• Miyabeacin: A new cyclodimer presents a potential role for willow in cancer therapy

  2020cites this paper
• The Skp2 Pathway: A Critical Target for Cancer Therapy.

  2020cites this paper
• Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma

  2019cites this paper
• p53, stem cell biology and childhood blastomas

  2019cites this paper
• The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors

  2019cites this paper
• High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells

  2019cites this paper
• Enzastaurin inhibits ABCB 1 mediated drug efflux independently of effects on protein kinase C signalling and the cellular

  2019cites this paper
• Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases

  2019cites this paper
• Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature

  2018cites this paper
• Methylation of the DKK3 promoter is associated with poor prognosis in patients with cervical adenocarcinoma.

  2018cites this paper
• Neuroblastoma treatment in the post-genomic era

  2017cites this paper
• MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma

  2017cites this paper
• Cellular Homeostasis and Antioxidant Response in Epithelial HT29 Cells on Titania Nanotube Arrays Surface

  2017cites this paper
• MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma

  2017cites this paper
• Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance

  2016cites this paper
• The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma

  2016cites this paper
• Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma

  2016cites this paper
• The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma

  2015cites this paper
• Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen

  2015cites this paper
• Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status

  2015cites this paper
• Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells

  2014cites this paper
• The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential

  2014cites this paper
• Resistance acquisition to MDM2 inhibitors.

  2014cites this paper
• Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma

  2014influential citation
• Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

  2013influential citation